Myopia Progression Study Comparing Low-Dose (0.01%) Atropine Eye Drops with a Control Group

Area of Science:

• Ophthalmology
• Pediatric Medicine
• Clinical Research

Background:

• Myopia progression is a significant concern in children's eye health.
• Current treatments aim to slow the rate of refractive error increase and axial elongation.
• Understanding the efficacy of low-dose atropine is crucial for pediatric myopia management.

Purpose of the Study:

• To evaluate the effectiveness of 0.01% atropine eye drops in controlling myopia progression in children.
• To compare the progression rates of spherical equivalent refractive error (SER) and axial length (AL) between atropine-treated and control groups.
• To analyze treatment response based on age.

Main Methods:

• A longitudinal study comparing two cohorts of myopic children (atropine vs. control).
• Inclusion criteria: myopia increase > -0.50 D or AL growth > 0.20 mm in the prior year.
• Data collection included examinations every 6 months for 18 months, measuring SER and AL.

Main Results:

• No statistically significant difference in SER change (p=0.295) or AL increase (p=0.160) between atropine and control groups at 18 months.
• Children under 9 years old demonstrated the lowest success rate (27.8%) and highest failure rate (63.2%) with 0.01% atropine (p=0.03).
• The mean change in SER was -0.73 D for atropine vs. -0.85 D for control; mean AL increase was 0.33 mm for atropine vs. 0.41 mm for control.

Conclusions:

• 0.01% atropine eye drops were not effective in slowing myopia progression in the observed pediatric population.
• Higher concentrations or combination therapies may be required for myopia control.
• Younger children (<9 years) require specific consideration due to lower treatment efficacy and higher progression potential.